Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?

TheMotleyFool

0 0

What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?

FibroGen (NASDAQ: FGEN) received some bad news recently with an overwhelmingly negative vote by a U.S. Food and Drug Administration (FDA) advisory committee related to anemia drug roxadustat. In this Motley Fool Live video recorded on July 19, 2021, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights discuss what's next for FibroGen after this disappointing vote.

Source Fool.com

Like: 0

FGEN

Share